318.73
0.83 (0.26%)
| Previous Close | 317.90 |
| Open | 318.49 |
| Volume | 300,590 |
| Avg. Volume (3M) | 420,590 |
| Market Cap | 12,536,104,960 |
| Price / Earnings (TTM) | 73.61 |
| Price / Earnings (Forward) | 62.89 |
| Price / Sales | 8.61 |
| Price / Book | 8.49 |
| 52 Weeks Range | |
| Earnings Date | 28 Jul 2026 |
| Profit Margin | 3.41% |
| Operating Margin (TTM) | 12.45% |
| Diluted EPS (TTM) | 1.09 |
| Quarterly Revenue Growth (YOY) | 16.30% |
| Quarterly Earnings Growth (YOY) | 256.50% |
| Total Debt/Equity (MRQ) | 18.19% |
| Current Ratio (MRQ) | 6.30 |
| Operating Cash Flow (TTM) | 179.16 M |
| Levered Free Cash Flow (TTM) | 135.83 M |
| Return on Assets (TTM) | 5.82% |
| Return on Equity (TTM) | 3.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Penumbra, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 3.0 |
| Average | 1.33 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 3.64% |
| % Held by Institutions | 91.96% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |